CLAIMS

1. Use of modified tripeptide or one of its pharmaceutically acceptable salts in the manufacture of a medicament for treating and/or preventing a disorder selected from:

- progeroid syndromes;
- striated muscle disorders; and,
- breast cancer, lung cancer, prostate cancer, kidney cancer, colorectal cancer and skin cancer;

wherein said modified tripeptide is selected from MG132, MG115, MG262, or MG110.

2. The use according to claim 1, wherein said medicament downregulates SRSF1.

3. The use according to claim 1, wherein said striated muscle disorder is chosen from oculopharyngeal muscular dystrophy.

4. The use according to claim 1, wherein said progeroid syndrome disorder is chosen from the group consisting of Hutchinson-Gilford progeria syndrome, atypical progeria syndrome, restrictive dermopathy, Nestor-Guillermo progeria syndrome, Werner syndrome, Bloom syndrome, Rothmund-Thomson syndrome, Cockayne syndrome, Xeroderma pigmentosum and trichothiodystrophy.

5. The use according to any one of Claims 1 to 4, wherein said modified tripeptide or one of its pharmaceutically acceptable salt, is formulated as an injectable formulation.

6. A dermatological, dermocosmetic or cosmetic use of a modified tripeptide or one of its pharmaceutically acceptable salt, for preventing and/or attenuating skin ageing, particularly human skin ageing, wherein said modified tripeptide is selected from MG132, MG115, MG262, or MG110 and is formulated for topical administration.

7. A cosmetic use of a modified tripeptide or one of its pharmaceutically acceptable salt, for attenuating physiological ageing, wherein said modified tripeptide is selected from MG132, MG115, MG262, or MG110.

8. The cosmetic use of Claim 7, for reducing wrinkles, file lines, and/or for preventing thinning of the skin and/or an aspect of soft and withered skin.